Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo Reports Second Quarter 2024 Financial Results

Tuesday, August 6, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. reported strong financial results for Q2 2024, achieving record revenue of $7.5 million. The company also noted 213 MyoPro authorizations and orders, alongside 550 new additions to its patient pipeline, bringing the total to 1,179 patients. These results highlight Myomo's growth and the increasing demand for its wearable medical robotics.
Price reaction · baseline $4.25 (2024-08-06T16:03:00.000Z) · hit during market hours · clean, no other MYO news in the window
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Record revenue of $7.5 million reported.
  • 213 MyoPro authorizations and orders achieved.
  • 550 new additions to the patient pipeline.

Full Press Release Details

Record revenue of $7.5 million
Record 213 MyoPro ® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end
BOSTON (August 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2024. Read more .

Frequently Asked Questions

What was Myomo's revenue for Q2 2024?

Myomo reported a record revenue of $7.5 million for Q2 2024.

How many MyoPro authorizations did Myomo achieve?

Myomo achieved 213 MyoPro authorizations and orders in Q2 2024.

What is the total number of patients in Myomo's pipeline?

At the end of Q2 2024, Myomo had 1,179 patients in its pipeline.

How many new additions were made to Myomo's pipeline?

Myomo added 550 new patients to its pipeline in Q2 2024.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo Q2 2024 financial results MyoPro revenue
Last updated: Aug 6, 2024

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk